$EHC
Encompass Health Corp Stock $ehc

$ehc Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000078516122000021 Filed on May 03, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$1.334B	$1.230B
YoY Change	8.39%	4.09%
Cost Of Revenue	$56.10M	$51.90M
YoY Change	8.09%	13.57%
Gross Profit	$1.278B	$1.179B
YoY Change	8.4%	3.71%
Gross Profit Margin	95.79%	95.78%
Selling, General & Admin	$845.3M	$746.0M
YoY Change	13.31%	1.51%
% of Gross Profit	66.17%	63.3%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$66.20M	$62.50M
YoY Change	5.92%	6.29%
% of Gross Profit	5.18%	5.3%
Operating Expenses	$1.094B	$970.8M
YoY Change	12.65%	1.84%
Operating Profit	$183.9M	$207.7M
YoY Change	-11.46%	30.38%
Interest Expense	$39.60M	$42.80M
YoY Change	-7.48%	-0.93%
% of Operating Profit	21.53%	20.61%
Other Income/Expense, Net	-$3.600M	$1.400M
YoY Change	-357.14%	-173.68%
Pretax Income	$141.3M	$167.3M
YoY Change	-15.54%	23.11%
Income Tax	$31.20M	$34.50M
% Of Pretax Income	22.08%	20.62%
Net Earnings	$87.50M	$107.3M
YoY Change	-18.45%	23.33%
Net Earnings / Revenue	6.56%	8.72%
Basic Earnings Per Share	$0.88	$1.08
Diluted Earnings Per Share	$0.87	$1.07
COMMON SHARES
Basic Shares Outstanding	99.20M shares	99.00M shares
Diluted Shares Outstanding	100.2M shares	100.2M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$94.20M	$223.9M
YoY Change	-57.93%	113.44%
Cash & Equivalents	$94.20M	$223.9M
Short-Term Investments
Other Short-Term Assets	$111.0M	$81.40M
YoY Change	36.36%	2.39%
Inventory
Prepaid Expenses
Receivables	$683.5M	$633.6M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$949.7M	$1.001B
YoY Change	-5.13%	27.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.904B	$2.529B
YoY Change	14.83%	26.23%
Goodwill	$2.457B	$2.319B
YoY Change	5.94%	0.29%
Intangibles	$410.6M	$419.2M
YoY Change	-2.05%	-9.79%
Long-Term Investments
YoY Change
Other Assets	$223.3M	$274.4M
YoY Change	-18.62%	-9.65%
Total Long-Term Assets	$5.994B	$5.541B
YoY Change	8.18%	3.51%
TOTAL ASSETS
Total Short-Term Assets	$949.7M	$1.001B
Total Long-Term Assets	$5.994B	$5.541B
Total Assets	$6.944B	$6.542B
YoY Change	6.14%	6.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$147.3M	$122.8M
YoY Change	19.95%	25.31%
Accrued Expenses	$564.4M	$552.2M
YoY Change	2.21%	23.26%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$42.80M	$137.2M
YoY Change	-68.8%	241.29%
Total Short-Term Liabilities	$754.5M	$812.2M
YoY Change	-7.1%	38.55%
LONG-TERM LIABILITIES
Long-Term Debt	$3.221B	$3.160B
YoY Change	1.94%	-4.87%
Other Long-Term Liabilities	$178.6M	$220.5M
YoY Change	-19.0%	35.03%
Total Long-Term Liabilities	$178.6M	$220.5M
YoY Change	-19.0%	35.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$754.5M	$812.2M
Total Long-Term Liabilities	$178.6M	$220.5M
Total Liabilities	$4.452B	$4.468B
YoY Change	-0.34%	3.74%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.974B	$1.655B
YoY Change
Total Liabilities & Shareholders Equity	$6.944B	$6.542B
YoY Change	6.14%	6.59%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	$87.50M	$107.3M
YoY Change	-18.45%	23.33%
Depreciation, Depletion And Amortization	$66.20M	$62.50M
YoY Change	5.92%	6.29%
Cash From Operating Activities	$218.9M	$158.5M
YoY Change	38.11%	440.96%
INVESTING ACTIVITIES
Capital Expenditures	$115.2M	$98.80M
YoY Change	16.6%	18.32%
Acquisitions		$0.00
YoY Change		-100.0%
Other Investing Activities	$7.900M	-$3.200M
YoY Change	-346.88%	100.0%
Cash From Investing Activities	-$123.1M	-$95.60M
YoY Change	28.77%	15.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$60.90M	-$77.50M
YoY Change	-21.42%	-209.0%
NET CHANGE
Cash From Operating Activities	$218.9M	$158.5M
Cash From Investing Activities	-$123.1M	-$95.60M
Cash From Financing Activities	-$60.90M	-$77.50M
Net Change In Cash	$34.90M	-$14.60M
YoY Change	-339.04%	-183.91%
FREE CASH FLOW
Cash From Operating Activities	$218.9M	$158.5M
Capital Expenditures	$115.2M	$98.80M
Free Cash Flow	$103.7M	$59.70M
YoY Change	73.7%	-210.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000785161
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38600000	USD
CY2022Q1	dei	Entity File Number EntityFileNumber	001-10315
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	Encompass Health Corporation
CY2022Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	110100000	USD
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	63-0860407
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	9001 Liberty Parkway
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Birmingham
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	AL
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	35242
CY2022Q1	dei	City Area Code CityAreaCode	205
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	967-7116
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	EHC
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	99802649	shares
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1333600000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1230400000	USD
CY2022Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	776000000.0	USD
CY2021Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	687200000	USD
CY2022Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	182100000	USD
CY2021Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	162300000	USD
CY2022Q1	ehc	Occupancy Cost OccupancyCost	20900000	USD
CY2021Q1	ehc	Occupancy Cost OccupancyCost	20200000	USD
CY2022Q1	us-gaap	Supplies Expense SuppliesExpense	56100000	USD
CY2021Q1	us-gaap	Supplies Expense SuppliesExpense	51900000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	48400000	USD
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-300000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	132800000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	66200000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	62500000	USD
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	1149700000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	1022700000	USD
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	39600000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	42800000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3600000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1400000	USD
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	900000	USD
CY2021Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1000000.0	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	141300000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	167300000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31200000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34500000	USD
CY2022Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	24900000	USD
CY2022Q1	us-gaap	Partners Capital Account Contributions PartnersCapitalAccountContributions	21400000	USD
CY2022Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	-14900000	USD
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	USD
CY2021Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	USD
CY2022Q1	us-gaap	Profit Loss ProfitLoss	110100000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	110100000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	132800000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	132800000	USD
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	22600000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	22600000	USD
CY2021Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	25500000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	25500000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	87500000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	87500000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	107300000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	107300000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99200000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99000000.0	shares
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.08
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100200000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100200000	shares
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.88
CY2021Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.08
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2021Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.88
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.87
CY2021Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.07
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2021Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.87
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.07
CY2022Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	87500000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	107300000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	121200000	USD
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2021Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	87500000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	107300000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94200000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54800000	USD
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	61000000.0	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	65100000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	683500000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	680300000	USD
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	111000000.0	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	949700000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	921400000	USD
CY2022Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2667100000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2601600000	USD
CY2021Q4	us-gaap	Assets Assets	6864900000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	236800000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	242000000.0	USD
CY2022Q1	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	42800000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	2456500000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	2427900000	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	410600000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	417500000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	223300000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	254500000	USD
CY2022Q1	us-gaap	Assets Assets	6944000000	USD
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	42800000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	38400000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	38400000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	147300000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	137600000	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	526000000.0	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	530000000.0	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	754500000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	748800000	USD
CY2022Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	3221300000	USD
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	3243900000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	208300000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	213100000	USD
CY2022Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	89700000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	86700000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	178600000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	173200000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	4452400000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	4465700000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	43200000	USD
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	42200000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	1973500000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1911300000	USD
CY2022Q1	us-gaap	Minority Interest MinorityInterest	474900000	USD
CY2021Q4	us-gaap	Minority Interest MinorityInterest	445700000	USD
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2448400000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2357000000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6944000000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6864900000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2357000000	USD
CY2022Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	108200000	USD
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	7600000	USD
CY2022Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.28
CY2022Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	28100000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7500000	USD
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2448400000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1970000000	USD
CY2021Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	130400000	USD
CY2021Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	15600000	USD
CY2021Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.28
CY2021Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	27800000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2800000	USD
CY2021Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	22400000	USD
CY2021Q1	us-gaap	Partners Capital Account Contributions PartnersCapitalAccountContributions	5800000	USD
CY2021Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	200000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2043000000	USD
CY2022Q1	us-gaap	Profit Loss ProfitLoss	110100000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	132800000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	66200000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	62500000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7500000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2800000	USD
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2000000.0	USD
CY2021Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	8700000	USD
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-7900000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2000000.0	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7300000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	55100000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-12000000.0	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1300000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	5600000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	5700000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	400000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-2200000	USD
CY2022Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-100000	USD
CY2021Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	USD
CY2022Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	108800000	USD
CY2021Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-3200000	USD
CY2021Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	25700000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	218900000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	158500000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	115200000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	98800000	USD
CY2022Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	7900000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-123100000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-95600000	USD
CY2022Q1	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	103900000	USD
CY2021Q1	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	3600000	USD
CY2022Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	130000000.0	USD
CY2021Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
CY2022Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	25000000.0	USD
CY2021Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	USD
CY2022Q1	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	20000000.0	USD
CY2021Q1	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	0	USD
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	7600000	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	15600000	USD
CY2022Q1	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	21400000	USD
CY2021Q1	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	4500000	USD
CY2022Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	28500000	USD
CY2021Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	29100000	USD
CY2022Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	21300000	USD
CY2021Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	27800000	USD
CY2022Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-6000000.0	USD
CY2021Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-5900000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-60900000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-77500000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	34900000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14600000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120300000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54800000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	310900000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94200000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	310900000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	155200000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	296300000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	224000000.0	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	65100000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	65400000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	400000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	21500000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120300000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	223900000	USD
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	61000000.0	USD
CY2021Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	62200000	USD
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10200000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	155200000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	296300000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	200000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	19700000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5900000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	17400000	USD
CY2022Q1	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	42	state
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1333600000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1230400000	USD
CY2022Q1	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1333600000	USD
CY2022Q1	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	87500000	USD
CY2021Q1	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1232700000	USD
CY2021Q1	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	107500000	USD
CY2022Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	3221300000	USD
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	3243900000	USD
CY2022Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	381000000.0	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	386800000	USD
CY2022Q1	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	3264100000	USD
CY2021Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	3286700000	USD
CY2022Q1	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	42800000	USD
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	42800000	USD
CY2022Q1	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	20700000	USD
CY2021Q1	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	23100000	USD
CY2022Q1	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	1900000	USD
CY2021Q1	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	2400000	USD
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	22600000	USD
CY2021Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	25500000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31200000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34500000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	110100000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	132800000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	22600000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	25500000	USD
CY2022Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	400000	USD
CY2021Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	500000	USD
CY2022Q1	ehc	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	87100000	USD
CY2021Q1	ehc	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	106800000	USD
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2021Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2022Q1	ehc	Net Income Loss Availableto Common Stockholders NetIncomeLossAvailabletoCommonStockholders	87100000	USD
CY2021Q1	ehc	Net Income Loss Availableto Common Stockholders NetIncomeLossAvailabletoCommonStockholders	106800000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99200000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99000000.0	shares
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.88
CY2021Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.08
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2021Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.88
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.08
CY2022Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	110100000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	132800000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	22600000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	25500000	USD
CY2022Q1	ehc	Income Loss From Continuing Operations Attributable To Common Shareholders Diluted IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted	87500000	USD
CY2021Q1	ehc	Income Loss From Continuing Operations Attributable To Common Shareholders Diluted IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted	107300000	USD
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2021Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	87500000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	107300000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100200000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100200000	shares
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.87
CY2021Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.07
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2021Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.87
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.07
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99200000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99000000.0	shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1000000.0	shares
CY2021Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1200000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100200000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100200000	shares
CY2022Q1	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	Contingencies and Other Commitments<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters—</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The False Claims Act allows private citizens, called “relators,” to institute civil proceedings on behalf of the United States alleging violations of the False Claims Act. These lawsuits, also known as “whistleblower” or “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” actions, can involve significant monetary damages, fines, attorneys’ fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases are sealed at the time of filing, which means knowledge of the information contained in the complaint typically is limited to the relator, the federal government, and the presiding court. The defendant in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action may remain unaware of the existence of a sealed complaint for years. While the complaint is under seal, the government reviews the merits of the case and may conduct a broad investigation and seek discovery from the defendant and other parties before deciding whether to intervene in the case and take the lead on litigating the claims. The court lifts the seal when the government makes its decision on whether to intervene. If the government decides not to intervene, the relator may elect to continue to pursue the lawsuit individually on behalf of the government. It is possible that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases brought pursuant to the False Claims Act.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the United States Department of Health and Human Services Office of Inspector General and the Centers for Medicare & Medicaid Services relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, Encompass Health refunding amounts to Medicare or other federal healthcare programs.</span></div>
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2022Q1	us-gaap	Assets Assets	6944000000	USD
CY2022Q1	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	3800000	USD
CY2021Q4	us-gaap	Assets Assets	6864900000	USD
CY2021Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	4000000.0	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	141300000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	167300000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1333600000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1230400000	USD

Files In Submission

Name	View Source	Status
0000785161-22-000021-index-headers.html	Edgar Link	pending
0000785161-22-000021-index.html	Edgar Link	pending
0000785161-22-000021.txt	Edgar Link	pending
0000785161-22-000021-xbrl.zip	Edgar Link	pending
ehc-20220331.htm	Edgar Link	pending
ehc-20220331.xsd	Edgar Link	pending
ehc-20220331_cal.xml	Edgar Link	unprocessable
ehc-20220331_def.xml	Edgar Link	unprocessable
ehc-20220331_htm.xml	Edgar Link	completed
ehc-20220331_lab.xml	Edgar Link	unprocessable
ehc-20220331_pre.xml	Edgar Link	unprocessable
ehc10q33122ex22.htm	Edgar Link	pending
ehc10q33122ex311.htm	Edgar Link	pending
ehc10q33122ex312.htm	Edgar Link	pending
ehc10q33122ex321.htm	Edgar Link	pending
ehc10q33122ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EHC
Encompass Health Corp Stock $ehc

2022 Q1 Form 10-Q Financial Statement

#000078516122000021 Filed on May 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EHC Encompass Health Corp Stock $ehc

2022 Q1 Form 10-Q Financial Statement

#000078516122000021 Filed on May 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EHC
Encompass Health Corp Stock $ehc